2003
Is it time for quadruple therapy to be first line?
Laine L. Is it time for quadruple therapy to be first line? 2003, 347-351. DOI: 10.1007/978-94-017-1763-2_36.ChaptersProton pump inhibitorsTriple therapyEradication ratePylori infectionCombination of PPIBismuth-based triple therapyPooled eradication ratesH. pylori infectionHelicobacter pylori infectionQuadruple therapyEarly therapyCurrent therapiesPump inhibitorsSeparate medicationsTherapyFirst lineInfectionStudies2–4Medications
2001
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals Of Internal Medicine 2001, 134: 361-9. PMID: 11242496, DOI: 10.7326/0003-4819-134-5-200103060-00008.Peer-Reviewed Original ResearchConceptsH. pylori eradication therapyNonulcer dyspepsiaPylori eradication therapyEradication therapyControl therapyOdds ratioH. pyloriHelicobacter pyloriDefinition of dyspepsiaDuplicate data extractionEnd of therapyH. pylori infectionAnalysis of trialsPylori infectionCombination therapyMethodologic qualityTreatment successDyspepsiaPersistent infectionReference listsTherapyPatientsStudy designPrimary investigatorPylori
2000
Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors
Laine, Ahnen, Mcclain, Solcia, Walsh. Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics 2000, 14: 651-668. PMID: 10848649, DOI: 10.1046/j.1365-2036.2000.00768.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProton pump inhibitor useProton pump inhibitorsLong-term acid suppressionGastric acid suppressionAcid suppressionPump inhibitorsInhibitor useBacterial overgrowthEnteric infectionsGastric adenocarcinomaHigh-dose proton pump inhibitorsCarcinoid formationLong-term proton pump inhibitor useEnterochromaffin-like cell hyperplasiaAdverse effectsChronic acid suppressionImportant clinical sequelaeLong-term protonGastrointestinal adverse effectsMalabsorption of fatVitamin B12 levelsCommon clinical problemH. pylori infectionVitamin B12 concentrationsGastric bacterial overgrowthHow to explain outcome differences in dyspepsia studies
Fennerty M, Laine L. How to explain outcome differences in dyspepsia studies. 2000, 421-425. DOI: 10.1007/978-94-011-3927-4_44.ChaptersNon-ulcer dyspepsiaPylori infectionAdequate observation periodPlacebo-controlled trialPeptic ulcer diseaseCause of symptomsH. pylori infectionHelicobacter pylori infectionClinical treatment trialsMajor aetiological factorUlcer diseaseTreatment trialsUpper abdomenAetiological factorsEarly trial resultsStudy populationOutcome differencesEpidemiological studiesH. pyloriDyspepsiaDiscordant resultsTrial resultsObservation periodSerious methodological deficienciesTrials
1999
Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing?
Faigel D, Vartan G, Knigge K, Laine L, Fennerty M, Margaret N, Marquis S. Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing? The American Journal Of Gastroenterology 1999, 94: ajg1999810. PMID: 10606304, DOI: 10.1111/j.1572-0241.1999.01510.x.Peer-Reviewed Original ResearchReview article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment
Schoenfeld, Kimmey, Scheiman, Bjorkman, Laine. Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment. Alimentary Pharmacology & Therapeutics 1999, 13: 1273-1285. PMID: 10540041, DOI: 10.1046/j.1365-2036.1999.00617.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsPylori infectionSerious gastrointestinal complicationsH. pylori infectionHelicobacter pylori infectionProton pump inhibitorsLowest possible dosagePotential of treatmentNSAID therapyNSAID useAnalgesic therapyCorticosteroid useGastrointestinal bleedingUlcer diseaseAntisecretory agentsPump inhibitorsChronic ingestionPain relieversNSAIDsComplicationsPatientsExact associationPossible dosageRoutine testingPast historyOnce-daily therapy for H. pylori infection: a randomized comparison of four regimens
Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. The American Journal Of Gastroenterology 1999, 94: 962. PMID: 10201465, DOI: 10.1111/j.1572-0241.1999.995_r.x.Peer-Reviewed Original ResearchConceptsH. pylori infectionEradication ratePylori infectionExtended-release formulationDaily therapyBreath testDaily triple therapyHigh-dose omeprazoleTreat eradication ratesCompletion of therapyHelicobacter pylori infectionRepeat breath testStudy medicationTriple therapyEndoscopic biopsyRandomized comparisonLack of complianceTherapyPilot studyInfectionFurther studiesClarithromycinOmamDaysSubjects
1998
Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection
Sadowski D, Cohen H, Laine L, Greenberg P, Goldstein J, Mihalov M, Cutler A. Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection. The American Journal Of Gastroenterology 1998, 93: ajg1998490. PMID: 9820383, DOI: 10.1111/j.1572-0241.1998.00604.x.Peer-Reviewed Original ResearchConceptsHelicobacter pylori infectionRapid urease testPylori infectionWhole blood testH. pyloriWhole bloodBlood testsUrease testPositive rapid urease testBlood antibody testH. pylori infectionProton pump inhibitorsH. pylori diagnosisDetection of antibodiesUpper endoscopyStudy enrollmentPump inhibitorsGastric biopsiesIgG antibodiesSerum testAntibody testOffice testsAntral tissueBacterial infectionsPatientsEffect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Annals Of Internal Medicine 1998, 129: 547-50. PMID: 9758575, DOI: 10.7326/0003-4819-129-7-199810010-00007.Peer-Reviewed Original ResearchConceptsUrea breath testProton pump inhibitor therapyBreath test resultsProton pump inhibitorsBreath testInhibitor therapyH. pyloriDiagnostic testingCompletion of therapyProportion of patientsNegative breath test resultH. pylori infectionUrea breath test resultsLansoprazole therapyFalse-negative resultsGastroenterology clinicPylori infectionPatientsHelicobacter pyloriTherapyDuration of conversionPyloriPositive resultsLansoprazoleDays
1996
Nonsteroidal Anti-Inflammatory Drug Gastropathy
Laine L. Nonsteroidal Anti-Inflammatory Drug Gastropathy. Gastrointestinal Endoscopy Clinics Of North America 1996, 6: 489-504. PMID: 8803564, DOI: 10.1016/s1052-5157(18)30351-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsSubepithelial hemorrhageNonsteroidal anti-inflammatory drug gastropathyDevelopment of NSAIDUpper abdominal symptomsGastric outlet obstructionHalf of patientsPost-treatment biopsiesH. pylori infectionReactive gastritisAbdominal symptomsMajor bleedingMinor bleedingNSAID useUlcer complicationsGastrointestinal bleedingNSAID ingestionNSAID gastropathyOutlet obstructionDuodenal ulcerGastric erosionsHistologic gastritisGastric lesionsGastric ulcerPeptic ulcer
1995
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial
LAINE L, COMINELLI F, SLOANE R, CASINI‐RAGGI V, MARIN‐SORENSEN M, WEINSTEIN WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial. Alimentary Pharmacology & Therapeutics 1995, 9: 127-135. PMID: 7605852, DOI: 10.1111/j.1365-2036.1995.tb00361.x.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsH. pylori infectionNSAID ingestionProstaglandin E2 productionHistological injuryWeek 1H. pyloriGastroduodenal injuryPylori infectionNegative subjectsE2 productionWeek 4Prostaglandin productionH. pylori-associated gastritisDouble-blind trialNormal baseline endoscopyAnti-inflammatory drugsBaseline endoscopyChemical gastritisGastroduodenal damagePlacebo b.Gastrointestinal injuryNSAID useGastric histologyNSAID group
1993
HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA
Laine L. HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA. Gastroenterology Clinics Of North America 1993, 22: 117-125. PMID: 8449561, DOI: 10.1016/s0889-8553(21)00267-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsH. pylori prevalenceGastric ulcerHistologic gastritisH. pyloriGastric injuryPylori prevalenceDuodenal ulcerGastric mucosaNoxious agentsInflammatory cell infiltrateH. pylori infectionNSAID usersCell infiltratePylori infectionDuodenal contentsNSAIDsUlcersGross injuryGastritisPatientsHelicobacter pyloriPyloriInjuryMucosaPrevalence